From the Journals

AD Pain, Sleep Scales Validated in Phase 3 Trials

What meaningful change looks like on skin pain and sleep disturbance scales

Share

5 Key Takeaways

  • 1

    3-point and 4-point reductions on SP-NRS and SD-NRS are clinically meaningful.

  • 2

    The study analyzed data from three phase 3 trials of rocatinlimab.

  • 3

    Skin pain and sleep disturbance are important outcomes in atopic dermatitis.

  • 4

    Intraclass correlation coefficients of at least 0.80 indicate high test-retest reliability.

  • 5

    Patient experiences captured by SP-NRS and SD-NRS may differ from clinician assessments.

Original Source(s)

AD Pain, Sleep Scales Validated in Phase 3 Trials

What meaningful change looks like on skin pain and sleep disturbance scales

  • by Jess Allerton

  • January 14, 2026

  • 3 min

Related Content

Rapid Itch Relief Seen with Nemolizumab

Researchers examined early itch and sleep outcomes with interleukin-31 pathway inhibition in atopic dermatitis and prurigo nodularis in phase 3 trial analyses.

Wildfires May Have Triggered Skin Disease Flare-ups in Northeastern United States

The number of visits to dermatologists for atopic dermatitis and eczema may have increased during the summer months of 2023 following the Canadian wildfires.

Cendakimab Shows Promise in Phase II Trial for Atopic Dermatitis